TY - JOUR
T1 - Application of peripheral blood progenitors to dose-intensive therapy of breast cancer
AU - Williams, Stephanie F.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1993/1
Y1 - 1993/1
N2 - Dose-intensive therapy has been used with increasing frequency in the treatment of women with breast carcinoma. This therapy requires chemotherapeutic agents that exhibit a steep dose-response curve and that have myelosuppression as their primary dose-limiting toxicity. To hasten or to rescue hematologic function after dose-intensive therapy, a hematopoietic rescue is used. The source of this rescue has traditionally been autologous bone marrow cells. However, circulating peripheral blood progenitor cells can also reconstitute hematopoiesis after dose-intensive therapy. The only prerequisites are that hematologic recovery is at least comparable and that survival is not adversely affected by the source of the stem cell graft. Peripheral blood progenitors can be procured in sufficient numbers after priming or mobilization with chemotherapy and/or hematopoietic growth factors. Peripheral blood progenitors collected in this fashion have led to complete and sustained hematologic reconstitution in women with metastatic breast cancer involving the marrow. In addition, peripheral blood progenitors can be used to augment autologous bone marrow grafts, further hastening hematologic recovery after dose-intensive therapy. Future studies will examine the role of peripheral blood progenitor support of multiple doseintensive cycles in women with breast cancer.
AB - Dose-intensive therapy has been used with increasing frequency in the treatment of women with breast carcinoma. This therapy requires chemotherapeutic agents that exhibit a steep dose-response curve and that have myelosuppression as their primary dose-limiting toxicity. To hasten or to rescue hematologic function after dose-intensive therapy, a hematopoietic rescue is used. The source of this rescue has traditionally been autologous bone marrow cells. However, circulating peripheral blood progenitor cells can also reconstitute hematopoiesis after dose-intensive therapy. The only prerequisites are that hematologic recovery is at least comparable and that survival is not adversely affected by the source of the stem cell graft. Peripheral blood progenitors can be procured in sufficient numbers after priming or mobilization with chemotherapy and/or hematopoietic growth factors. Peripheral blood progenitors collected in this fashion have led to complete and sustained hematologic reconstitution in women with metastatic breast cancer involving the marrow. In addition, peripheral blood progenitors can be used to augment autologous bone marrow grafts, further hastening hematologic recovery after dose-intensive therapy. Future studies will examine the role of peripheral blood progenitor support of multiple doseintensive cycles in women with breast cancer.
KW - breast cancer
KW - high-dose chemotherapy
KW - peripheral blood progenitor cells
UR - http://www.scopus.com/inward/record.url?scp=0027275106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027275106&partnerID=8YFLogxK
U2 - 10.1007/BF00668357
DO - 10.1007/BF00668357
M3 - Article
C2 - 8104542
AN - SCOPUS:0027275106
SN - 0167-6806
VL - 26
SP - S25-S29
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -